Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 7 Sept 2026Clinical review pending
!
Inflammatory disease does not explain away a painful red eye
Eye pain, redness, photophobia or blurred vision can indicate acute anterior uveitis. Infection and other ocular emergencies may produce similar symptoms, including in someone already receiving immunosuppression.
Action: Arrange immediate same-day ophthalmological assessment for symptoms of acute anterior uveitis, following NICE NG65. Sudden marked visual loss or a suspected posterior inflammatory emergency requires direct emergency eye-service contact.
Synopsis
Recognise inflammatory eye disease associated with rheumatological conditions, investigate relevant systemic clues and coordinate safe ocular treatment without overlooking infection.
Uveitis may be the first clue to systemic inflammatory disease, but many episodes lack an identified systemic cause.
Ask about inflammatory back pain, joint symptoms, psoriasis, bowel inflammation and recurrent oral or genital ulcers.
Describe which ocular structures are inflamed; anterior, intermediate, posterior and panuveitic disease require different assessment and treatment.
Key red flags
A painful red eye with light intolerance or reduced vision needs same-day ophthalmic assessment.
Investigation priorities
01
Slit-lamp examination with pressure assessmentFirst step
Confirm anterior inflammation and assess associated structural or pressure complications.
Management branches
Acute symptomsEstablish the ocular diagnosis today
Pain, redness, photophobia or blurred vision suggests acute anterior uveitis.
Document available visual findings and medication exposure while avoiding empirical escalation of steroid for an undiagnosed red eye.
Key medicines
Pred Forte 1% prednisolone acetate suspension for specialist-confirmed inflammationThe adult UK product regimen is one or two drops in the affected eye two to four times daily; during the first 24–48 hours, two drops every hour may be prescribed. The ophthalmologist determines subsequent frequency, taper and stop point from inflammation control.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.